$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

$lsta Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000032001724000007 Filed on February 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.360M	$3.012M	$12.97M
YoY Change	-8.32%	-10.62%	-8.25%
% of Gross Profit
Research & Development	$3.241M	$3.013M	$12.73M
YoY Change	1.95%	-4.95%	-2.55%
% of Gross Profit
Depreciation & Amortization	$29.00K	$47.00K	$189.0K
YoY Change	-3.33%	-6.0%	173.91%
% of Gross Profit
Operating Expenses	$6.601M	$6.025M	$25.71M
YoY Change	-3.55%	-7.87%	-55.37%
Operating Profit	-$6.601M		-$25.71M
YoY Change	-3.55%		-55.37%
Interest Expense	$589.0K	$671.0K	$2.724M
YoY Change	-12.09%	19.82%	159.43%
% of Operating Profit
Other Income/Expense, Net	$402.0K	-$11.00K	$2.538M
YoY Change	-38.81%	10.0%	182.94%
Pretax Income	-$6.199M	-$5.365M	-$23.17M
YoY Change	0.19%	-10.43%	-59.14%
Income Tax	-$798.0K	$0.00	-$2.330M
% Of Pretax Income
Net Earnings	-$5.401M	-$5.365M	-$20.84M
YoY Change	-12.7%	-10.43%	-61.57%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.65		-$2.58
Diluted Earnings Per Share	-$0.65	-$0.66	-$2.58
COMMON SHARES
Basic Shares Outstanding	8.307M shares	8.139M shares	8.073M shares
Diluted Shares Outstanding	8.294M shares		8.073M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$43.35M	$50.54M	$50.54M
YoY Change	-29.05%	-27.0%	-26.97%
Cash & Equivalents	$21.81M	$22.59M	$22.59M
Short-Term Investments	$21.54M	$27.94M	$27.94M
Other Short-Term Assets	$4.210M	$3.389M	$3.389M
YoY Change	0.24%	25.52%	25.52%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$47.56M	$53.92M	$53.92M
YoY Change	-27.17%	-24.98%	-25.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$146.0K	$175.0K	$483.0K
YoY Change	-44.27%	-40.88%	-39.63%
Goodwill
YoY Change
Intangibles	$400.0K	$400.0K
YoY Change	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$290.0K	$332.0K	$24.00K
YoY Change	-35.41%	-37.12%
Total Long-Term Assets	$681.0K	$770.0K	$770.0K
YoY Change	-33.75%	-33.51%	-30.0%
TOTAL ASSETS
Total Short-Term Assets	$47.56M	$53.92M	$53.92M
Total Long-Term Assets	$681.0K	$770.0K	$770.0K
Total Assets	$48.24M	$54.69M	$54.69M
YoY Change	-27.27%	-25.11%	-25.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.263M	$2.421M	$2.421M
YoY Change	-5.82%	-8.81%	-10.33%
Accrued Expenses	$4.070M	$4.169M	$4.169M
YoY Change	3.17%	11.83%	12.68%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.333M	$6.590M	$6.590M
YoY Change	0.89%	3.24%	2.97%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$164.0K	$210.0K	$210.0K
YoY Change	-51.34%	-35.78%	-30.0%
Total Long-Term Liabilities	$164.0K	$210.0K	$210.0K
YoY Change	-51.34%	-35.78%	-30.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.333M	$6.590M	$6.590M
Total Long-Term Liabilities	$164.0K	$210.0K	$210.0K
Total Liabilities	$5.497M	$6.800M	$6.546M
YoY Change	-2.24%	1.34%	0.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$533.5M	-$528.1M
YoY Change	3.91%	4.11%
Common Stock	$8.000K	$8.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$43.00M	$48.15M	$48.15M
YoY Change
Total Liabilities & Shareholders Equity	$48.24M	$54.69M	$54.69M
YoY Change	-27.27%	-25.11%	-25.08%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$5.401M	-$5.365M	-$20.84M
YoY Change	-12.7%	-10.43%	-61.57%
Depreciation, Depletion And Amortization	$29.00K	$47.00K	$189.0K
YoY Change	-3.33%	-6.0%	173.91%
Cash From Operating Activities	-$7.027M	-$4.069M	-$20.03M
YoY Change	-14.26%	-37.11%	-5.38%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$6.436M	-$5.714M	$10.10M
YoY Change	50.02%	-180.03%	-65.4%
Cash From Investing Activities	$6.436M	-$5.714M	$10.10M
YoY Change	50.06%	-180.48%	-65.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$321.0K
YoY Change			646.51%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$142.0K	24.00K	$385.0K
YoY Change	67.06%	20.0%	-271.88%
NET CHANGE
Cash From Operating Activities	-$7.027M	-4.069M	-$20.03M
Cash From Investing Activities	$6.436M	-5.714M	$10.10M
Cash From Financing Activities	-$142.0K	24.00K	$385.0K
Net Change In Cash	-$788.0K	-9.759M	-$9.561M
YoY Change	-80.3%	-1601.38%	-227.36%
FREE CASH FLOW
Cash From Operating Activities	-$7.027M	-$4.069M	-$20.03M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$4.069M	-$20.03M
YoY Change		-37.4%	-6.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-33650
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-2343568
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	110 Allen Road, 2nd Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Basking Ridge
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07920
CY2023	dei	City Area Code CityAreaCode	908
CY2023	dei	Local Phone Number LocalPhoneNumber	842-0100
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	LSTA
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22593000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	27942000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3389000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	175000	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	263000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	332000	usd
CY2023Q4	us-gaap	Assets Assets	54694000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2421000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4169000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6590000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	210000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6800000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Profit Loss ProfitLoss	-20840000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-20840000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-25708000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-57601000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	1052000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	66324000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000320017
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023	dei	Entity Registrant Name EntityRegistrantName	LISATA THERAPEUTICS, INC.
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	25100000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8307433	shares
CY2023	dei	Auditor Firm AuditorFirmId	248
CY2023	dei	Auditor Name AuditorName	GRANT THORNTON LLP
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32154000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	37072000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2650000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	53924000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	71876000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	296000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	334000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	528000	usd
CY2022Q4	us-gaap	Assets Assets	73034000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2655000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3728000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6383000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	327000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6710000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8150635	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7866799	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8149897	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7866061	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	576971000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	574548000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	738	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	738	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	708000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	708000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-528081000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-507241000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-42000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-29000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	48148000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	66578000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-254000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-254000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	47894000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	66324000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54694000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73034000	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	12734000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	13067000	usd
CY2023	lsta	In Process Research And Development InProcessResearchAndDevelopment	0	usd
CY2022	lsta	In Process Research And Development InProcessResearchAndDevelopment	30393000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12974000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14141000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	25708000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	57601000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2538000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23170000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-56704000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2330000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2479000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-20840000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-54225000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	0	usd
CY2022	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20840000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-54225000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.58
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.58
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.47
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.47
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8073000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8073000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5180000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5180000	shares
CY2022	us-gaap	Profit Loss ProfitLoss	-54225000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	12000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	52000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-25000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-13000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	41000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-20853000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-54184000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20853000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54184000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	92000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-54225000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2367000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	43000	usd
CY2022	lsta	Stock Issued During Period Value New Issues Related To Merger StockIssuedDuringPeriodValueNewIssuesRelatedToMerger	26098000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	52000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-11000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-11000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-20840000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1947000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	321000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	155000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	12000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-25000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-25000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	47894000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-54225000	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2038000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2636000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	189000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	69000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-3000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2023	lsta	In Process Research And Development Expenses InProcessResearchAndDevelopmentExpenses	0	usd
CY2022	lsta	In Process Research And Development Expenses InProcessResearchAndDevelopmentExpenses	30393000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	960000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-788000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	824000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	845000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-274000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-237000	usd
CY2023	lsta	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	88000	usd
CY2022	lsta	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-223000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20032000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21170000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	98479000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	89687000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	108581000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	122203000	usd
CY2023	lsta	Payments For Asset Acquisition Costs Net PaymentsForAssetAcquisitionCostsNet	0	usd
CY2022	lsta	Payments For Asset Acquisition Costs Net PaymentsForAssetAcquisitionCostsNet	3320000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	285000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10102000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28911000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	155000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	91000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	267000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	321000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	385000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-224000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-16000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9561000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7507000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32154000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24647000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22593000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32154000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	23580000	usd
CY2023	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	usd
CY2022	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	2136000	usd
CY2022Q3	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	1227776	shares
CY2022Q3	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.52
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger, which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (“IPR&D”). Accordingly, actual results could differ from those estimates and assumptions.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and may exceed federally insured limits. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div>
CY2023	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight-line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div>
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	400000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	71000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	71000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	71000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	71000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	71000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	71000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	71000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	71000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	44662000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	44657000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	64758000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	64740000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	44657000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	64740000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	44662000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	44657000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	64758000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	64740000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	44662000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	44657000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	64758000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	64740000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	661000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	713000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	486000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	417000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	175000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	296000	usd
CY2023	us-gaap	Depreciation Depreciation	100000	usd
CY2022	us-gaap	Depreciation Depreciation	100000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	2665000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	2586000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	168000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	180000	usd
CY2023Q4	lsta	Research And Development Liabilities ResearchAndDevelopmentLiabilities	1046000	usd
CY2022Q4	lsta	Research And Development Liabilities ResearchAndDevelopmentLiabilities	785000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	57000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	66000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	233000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	111000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	4169000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	3728000	usd
CY2023Q4	lsta	Number Of Offices Under Operating Leases NumberOfOfficesUnderOperatingLeases	1	office
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	308000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	487000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	308000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	487000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	168000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	180000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	137000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	305000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	305000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	485000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09625
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	190000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	143000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	333000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	28000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	305000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	333333	shares
CY2022Q3	lsta	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed Through Merger In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedThroughMergerInPeriod	1227776	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1391352	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.83
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	187600	usd
CY2022Q4	lsta	Common Stock Warrants Shares CommonStockWarrantsShares	1423774	shares
CY2022Q4	lsta	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	42.57
CY2022	lsta	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P3Y4M13D
CY2022Q4	lsta	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	182846	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.45
CY2023	lsta	Warrants Granted WarrantsGranted	0	shares
CY2023	lsta	Weighted Average Exercise Price Warrants Granted WeightedAverageExercisePriceWarrantsGranted	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	82500	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.88
CY2023	lsta	Warrants Exercised WarrantsExercised	0	shares
CY2023	lsta	Weighted Average Exercise Price Warrants Exercised WeightedAverageExercisePriceWarrantsExercised	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	144594	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.63
CY2023	lsta	Warrants Canceled WarrantsCanceled	0	shares
CY2023	lsta	Weighted Average Exercise Price Warrants Canceled WeightedAverageExercisePriceWarrantsCanceled	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	24603	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	29.60
CY2023	lsta	Warrants Expired WarrantsExpired	2000	shares
CY2023	lsta	Weighted Average Exercise Price Warrants Expired WeightedAverageExercisePriceWarrantsExpired	88.35
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1322501	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.81
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y21D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	164100	usd
CY2023Q4	lsta	Common Stock Warrants Shares CommonStockWarrantsShares	1421744	shares
CY2023Q4	lsta	Weighted Average Exercise Price Warrants Outstanding WeightedAverageExercisePriceWarrantsOutstanding	42.51
CY2023	lsta	Weighted Average Remaining Contractual Termwarrantoutstanding WeightedAverageRemainingContractualTermwarrantoutstanding	P2Y5M1D
CY2023Q4	lsta	Aggregate Intrinsic Value Warrants Outstanding AggregateIntrinsicValueWarrantsOutstanding	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1319053	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.83
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	164100	usd
CY2023Q4	lsta	Sharesvestedandexpectedtovest Sharesvestedandexpectedtovest	1421744	shares
CY2023Q4	lsta	Weighted Average Exercise Price Warrants Vested And Expected To Vest WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest	42.51
CY2023	lsta	Weighted Average Remaining Contractual Term Warrants Vestedand Expectto Vest WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest	P2Y5M1D
CY2023Q4	lsta	Aggregate Intrinsic Value Warrantsvestedandexpectedtovest AggregateIntrinsicValueWarrantsvestedandexpectedtovest	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1229103	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	11.25
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y10M2D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	159900	usd
CY2023Q4	lsta	Warrants Vested WarrantsVested	1421744	shares
CY2023Q4	lsta	Weighted Average Exercise Price Warrants Exercisable WeightedAverageExercisePriceWarrantsExercisable	42.51
CY2023	lsta	Weighted Average Remaining Contractual Termwarrantsvested WeightedAverageRemainingContractualTermwarrantsvested	P2Y5M1D
CY2023Q4	lsta	Aggregate Intrinsic Value Warrantsvested AggregateIntrinsicValueWarrantsvested	0	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2038000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2636000	usd
CY2023	lsta	Share Based Compensation Arrangement By Share Based Payment Award Shares Modified ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesModified	186600	shares
CY2023Q4	lsta	Number Of Terminated Employee NumberOfTerminatedEmployee	1	employee
CY2023	lsta	Share Based Payment Arrangement Incremental Expense ShareBasedPaymentArrangementIncrementalExpense	258000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-21477000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-56175000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1693000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-529000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23170000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-56704000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2330000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2479000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2330000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2479000	usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	usd
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-2330000	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-2479000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2330000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2479000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	6662000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4865000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-11908000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	875000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7238000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	809000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	8604000	usd
CY2023	lsta	Effective Income Tax Rate Reconciliation Tax Reconciliation Amount EffectiveIncomeTaxRateReconciliationTaxReconciliationAmount	58000	usd
CY2022	lsta	Effective Income Tax Rate Reconciliation Tax Reconciliation Amount EffectiveIncomeTaxRateReconciliationTaxReconciliationAmount	1000	usd
CY2023	lsta	Effective Income Tax Rate Reconciliation Changein State Deferred Amount EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount	569000	usd
CY2022	lsta	Effective Income Tax Rate Reconciliation Changein State Deferred Amount EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount	162000	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	166000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-25000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-22000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-21000	usd
CY2023	lsta	Effective Income Tax Rate Reconciliation Section382 Nol Limitation Amount EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount	0	usd
CY2022	lsta	Effective Income Tax Rate Reconciliation Section382 Nol Limitation Amount EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount	18553000	usd
CY2023	lsta	Effective Income Tax Rate Reconciliation Sale Of State Net Operating Losses EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses	-2330000	usd
CY2022	lsta	Effective Income Tax Rate Reconciliation Sale Of State Net Operating Losses EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses	-2479000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2526000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-22602000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2330000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2479000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12736000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13132000	usd
CY2023Q4	lsta	Deferred Tax Assets Right Of Use Liability DeferredTaxAssetsRightOfUseLiability	86000	usd
CY2022Q4	lsta	Deferred Tax Assets Right Of Use Liability DeferredTaxAssetsRightOfUseLiability	136000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2370000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3027000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	889000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	944000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	5018000	usd
CY2023Q4	lsta	Deferred Tax Assets Accumulated Depreciation DeferredTaxAssetsAccumulatedDepreciation	10000	usd
CY2022Q4	lsta	Deferred Tax Assets Accumulated Depreciation DeferredTaxAssetsAccumulatedDepreciation	14000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	218000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	118000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	638000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	579000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23609000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22968000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	87000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	137000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	99000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	87000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	236000	usd
CY2023Q4	lsta	Net Deferred Tax Assets And Liabilities Gross NetDeferredTaxAssetsAndLiabilitiesGross	23522000	usd
CY2022Q4	lsta	Net Deferred Tax Assets And Liabilities Gross NetDeferredTaxAssetsAndLiabilitiesGross	22732000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23522000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22732000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	88200000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	34000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	344000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	344000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	344000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	344000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	344000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	344000	usd
CY2022Q1	lsta	Proceeds From Sale Of Net Operating Losses Njeda Program Gross ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross	25900000	usd
CY2022Q1	lsta	Proceeds From Sale Of Net Operating Losses Njeda Program ProceedsFromSaleOfNetOperatingLossesNJEDAProgram	2200000	usd
CY2022Q1	lsta	Loss On Sale Of Net Operating Losses LossOnSaleOfNetOperatingLosses	100000	usd
CY2023Q4	lsta	Income Tax Incentive Receivable IncomeTaxIncentiveReceivable	1000000	usd
CY2022Q4	lsta	Income Tax Incentive Receivable IncomeTaxIncentiveReceivable	700000	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000320017-24-000007-index-headers.html	Edgar Link	pending
0000320017-24-000007-index.html	Edgar Link	pending
0000320017-24-000007.txt	Edgar Link	pending
0000320017-24-000007-xbrl.zip	Edgar Link	pending
ex102equityplanscomplete.htm	Edgar Link	pending
ex102equityplanscomplete001.jpg	Edgar Link	pending
ex102equityplanscomplete002.jpg	Edgar Link	pending
ex102equityplanscomplete003.jpg	Edgar Link	pending
ex102equityplanscomplete004.jpg	Edgar Link	pending
ex102equityplanscomplete005.jpg	Edgar Link	pending
ex102equityplanscomplete006.jpg	Edgar Link	pending
ex102equityplanscomplete007.jpg	Edgar Link	pending
ex102equityplanscomplete008.jpg	Edgar Link	pending
ex102equityplanscomplete009.jpg	Edgar Link	pending
ex102equityplanscomplete010.jpg	Edgar Link	pending
ex102equityplanscomplete011.jpg	Edgar Link	pending
ex102equityplanscomplete012.jpg	Edgar Link	pending
ex102equityplanscomplete013.jpg	Edgar Link	pending
ex102equityplanscomplete014.jpg	Edgar Link	pending
ex102equityplanscomplete015.jpg	Edgar Link	pending
ex102equityplanscomplete016.jpg	Edgar Link	pending
ex102equityplanscomplete017.jpg	Edgar Link	pending
ex102equityplanscomplete018.jpg	Edgar Link	pending
ex102equityplanscomplete019.jpg	Edgar Link	pending
ex102equityplanscomplete020.jpg	Edgar Link	pending
ex102equityplanscomplete021.jpg	Edgar Link	pending
ex102equityplanscomplete022.jpg	Edgar Link	pending
ex102equityplanscomplete023.jpg	Edgar Link	pending
ex102equityplanscomplete024.jpg	Edgar Link	pending
ex102equityplanscomplete025.jpg	Edgar Link	pending
ex102equityplanscomplete026.jpg	Edgar Link	pending
ex102equityplanscomplete027.jpg	Edgar Link	pending
ex102equityplanscomplete028.jpg	Edgar Link	pending
ex102equityplanscomplete029.jpg	Edgar Link	pending
ex102equityplanscomplete030.jpg	Edgar Link	pending
ex102equityplanscomplete031.jpg	Edgar Link	pending
ex102equityplanscomplete032.jpg	Edgar Link	pending
ex102equityplanscomplete033.jpg	Edgar Link	pending
ex102equityplanscomplete034.jpg	Edgar Link	pending
ex102equityplanscomplete035.jpg	Edgar Link	pending
ex102equityplanscomplete036.jpg	Edgar Link	pending
ex102equityplanscomplete037.jpg	Edgar Link	pending
ex102equityplanscomplete038.jpg	Edgar Link	pending
ex102equityplanscomplete039.jpg	Edgar Link	pending
ex102equityplanscomplete040.jpg	Edgar Link	pending
ex102equityplanscomplete041.jpg	Edgar Link	pending
ex102equityplanscomplete042.jpg	Edgar Link	pending
ex102equityplanscomplete043.jpg	Edgar Link	pending
ex102equityplanscomplete044.jpg	Edgar Link	pending
ex102equityplanscomplete045.jpg	Edgar Link	pending
ex102equityplanscomplete046.jpg	Edgar Link	pending
ex102equityplanscomplete047.jpg	Edgar Link	pending
ex102equityplanscomplete048.jpg	Edgar Link	pending
ex102equityplanscomplete049.jpg	Edgar Link	pending
ex102equityplanscomplete050.jpg	Edgar Link	pending
ex102equityplanscomplete051.jpg	Edgar Link	pending
ex102equityplanscomplete052.jpg	Edgar Link	pending
ex102equityplanscomplete053.jpg	Edgar Link	pending
ex102equityplanscomplete054.jpg	Edgar Link	pending
ex102equityplanscomplete055.jpg	Edgar Link	pending
ex102equityplanscomplete056.jpg	Edgar Link	pending
ex102equityplanscomplete057.jpg	Edgar Link	pending
ex102equityplanscomplete058.jpg	Edgar Link	pending
ex102equityplanscomplete059.jpg	Edgar Link	pending
ex102equityplanscomplete060.jpg	Edgar Link	pending
ex102equityplanscomplete061.jpg	Edgar Link	pending
ex102equityplanscomplete062.jpg	Edgar Link	pending
ex102equityplanscomplete063.jpg	Edgar Link	pending
ex102equityplanscomplete064.jpg	Edgar Link	pending
ex102equityplanscomplete065.jpg	Edgar Link	pending
ex102equityplanscomplete066.jpg	Edgar Link	pending
ex102equityplanscomplete067.jpg	Edgar Link	pending
ex102equityplanscomplete068.jpg	Edgar Link	pending
ex102equityplanscomplete069.jpg	Edgar Link	pending
ex102equityplanscomplete070.jpg	Edgar Link	pending
ex102equityplanscomplete071.jpg	Edgar Link	pending
ex102equityplanscomplete072.jpg	Edgar Link	pending
ex102equityplanscomplete073.jpg	Edgar Link	pending
ex102equityplanscomplete074.jpg	Edgar Link	pending
ex102equityplanscomplete075.jpg	Edgar Link	pending
ex102equityplanscomplete076.jpg	Edgar Link	pending
ex102equityplanscomplete077.jpg	Edgar Link	pending
ex102equityplanscomplete078.jpg	Edgar Link	pending
ex102equityplanscomplete079.jpg	Edgar Link	pending
ex102equityplanscomplete080.jpg	Edgar Link	pending
ex102equityplanscomplete081.jpg	Edgar Link	pending
ex102equityplanscomplete082.jpg	Edgar Link	pending
ex102equityplanscomplete083.jpg	Edgar Link	pending
ex102equityplanscomplete084.jpg	Edgar Link	pending
ex102equityplanscomplete085.jpg	Edgar Link	pending
ex105esppplancompleteex.htm	Edgar Link	pending
ex105esppplancompleteex001.jpg	Edgar Link	pending
ex105esppplancompleteex002.jpg	Edgar Link	pending
ex105esppplancompleteex003.jpg	Edgar Link	pending
ex105esppplancompleteex004.jpg	Edgar Link	pending
ex105esppplancompleteex005.jpg	Edgar Link	pending
ex105esppplancompleteex006.jpg	Edgar Link	pending
ex105esppplancompleteex007.jpg	Edgar Link	pending
ex105esppplancompleteex008.jpg	Edgar Link	pending
ex105esppplancompleteex009.jpg	Edgar Link	pending
ex105esppplancompleteex010.jpg	Edgar Link	pending
ex105esppplancompleteex011.jpg	Edgar Link	pending
ex105esppplancompleteex012.jpg	Edgar Link	pending
ex105esppplancompleteex013.jpg	Edgar Link	pending
ex105esppplancompleteex014.jpg	Edgar Link	pending
ex105esppplancompleteex015.jpg	Edgar Link	pending
ex105esppplancompleteex016.jpg	Edgar Link	pending
ex105esppplancompleteex017.jpg	Edgar Link	pending
ex105esppplancompleteex018.jpg	Edgar Link	pending
ex105esppplancompleteex019.jpg	Edgar Link	pending
ex105esppplancompleteex020.jpg	Edgar Link	pending
ex105esppplancompleteex021.jpg	Edgar Link	pending
ex105esppplancompleteex022.jpg	Edgar Link	pending
ex105esppplancompleteex023.jpg	Edgar Link	pending
ex105esppplancompleteex024.jpg	Edgar Link	pending
ex105esppplancompleteex025.jpg	Edgar Link	pending
ex105esppplancompleteex026.jpg	Edgar Link	pending
ex105esppplancompleteex027.jpg	Edgar Link	pending
ex105esppplancompleteex028.jpg	Edgar Link	pending
ex105esppplancompleteex029.jpg	Edgar Link	pending
ex191policyoninsidertrad.htm	Edgar Link	pending
ex191policyoninsidertrad001.jpg	Edgar Link	pending
ex191policyoninsidertrad002.jpg	Edgar Link	pending
ex191policyoninsidertrad003.jpg	Edgar Link	pending
ex191policyoninsidertrad004.jpg	Edgar Link	pending
ex191policyoninsidertrad005.jpg	Edgar Link	pending
ex191policyoninsidertrad006.jpg	Edgar Link	pending
ex191policyoninsidertrad007.jpg	Edgar Link	pending
ex191policyoninsidertrad008.jpg	Edgar Link	pending
ex191policyoninsidertrad009.jpg	Edgar Link	pending
ex191policyoninsidertrad010.jpg	Edgar Link	pending
ex211to10k20231231.htm	Edgar Link	pending
ex311_20231231-q4.htm	Edgar Link	pending
ex32_20231231.htm	Edgar Link	pending
ex97incentiverecoupmentp.htm	Edgar Link	pending
ex97incentiverecoupmentp001.jpg	Edgar Link	pending
ex97incentiverecoupmentp002.jpg	Edgar Link	pending
ex97incentiverecoupmentp003.jpg	Edgar Link	pending
exh2312023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lsta-20231231.htm	Edgar Link	pending
lsta-20231231.xsd	Edgar Link	pending
lsta-20231231_g1.jpg	Edgar Link	pending
lsta-20231231_g2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
lsta-20231231_cal.xml	Edgar Link	unprocessable
lsta-20231231_def.xml	Edgar Link	unprocessable
lsta-20231231_lab.xml	Edgar Link	unprocessable
lsta-20231231_pre.xml	Edgar Link	unprocessable
lsta-20231231_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

2024 Q1 Form 10-K Financial Statement

#000032001724000007 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA LISATA THERAPEUTICS, INC. Stock $lsta

2024 Q1 Form 10-K Financial Statement

#000032001724000007 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta